The news: Novo Nordisk is cutting the price of its diabetes drug, Ozempic, by about half, from nearly $1,000 to $499 per month. It’s offering cheaper Ozempic via its direct-to-consumer (D2C) NovoCare Pharmacy and at retail through a new GoodRx partnership.

Zooming in: Novo’s first collaboration with GoodRx includes both Ozempic and Wegovy (Novo’s weight loss version of semaglutide), also for $499.

• Novo’s deal with the Rx drug discounter extends the lower cash price to more than 70,000 local pharmacy counters.
• GoodRx’s stock rose 37%, while Novo’s US shares climbed more than 5% on Tuesday after the news was announced.
• Almost 17 million people searched GoodRx for GLP-1 savings or information last year, a 22% increase YoY, per GoodRx.